NIH #5R21CA182941-02
PDE Inhibition by Sulindac Sulfide Amide Derivatives for Lung Cancer Chemoprevention
- Amount
- $165K
- Period
- 2015-02-01 → 2017-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF SOUTH ALABAMA
Cancer Genomics and Diagnostics · Cancer Research
2 total · 0 active
NIH #5R21CA182941-02
Awarded at UNIVERSITY OF SOUTH ALABAMA
NIH #1R21CA182941-01A1
Awarded at UNIVERSITY OF SOUTH ALABAMA
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
Nature Communications · 2025-12-12 · 4 citations
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma
Nature · 2025-12-10 · 8 citations
2025-11-26
2025-11-26
2025-11-26
2025-11-26
2025-11-26
2025-11-26
2025-11-26
Biostatisticians Meet <scp>AI</scp> : Navigating Shifts While Preserving Principles
Statistics in Medicine · 2025-09-01 · 1 citations
The mutagenic forces shaping the genomes of lung cancer in never smokers
Nature · 2025-07-02 · 37 citations
Materials Today Communications · 2025-07-01 · 4 citations
A Thiopurine-like Mutagenic Process Defines TGCT SubtypesPreprint
Research Square · 2025-06-16
Clinical Cancer Research · 2025-06-13
APOBEC affects tumor evolution and age at onset of lung cancer in smokers
Nature Communications · 2025-05-21 · 8 citations
Precision Clinical Medicine · 2025-04-09 · 5 citations
Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotranspositionPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-03-16 · 6 citations
HLA-DQB1*03:01 and risk of HBV-related HCC
Hepatology · 2025-03-14 · 3 citations
PLoS Genetics · 2024-10-23 · 2 citations
PubMed · 2024-10-01